Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?
Presented at the 49th Annual Meeting of the Midwest Surgical Association, Mackinac Island, MI, August 6–9, 2006
Received 12 August 2006; received in revised form 20 September 2006
Abstract
Background
Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood.
Methods
One institution's experience with duodenal adenocarcinoma from 1984 to 2005 is reviewed. Clinicopathologic data were analyzed, and overall survival was estimated using Kaplan-Meier curves with log-rank test.
Results
Of the 52 patients, 35 (67%) underwent potentially curative surgery; 31 survived the postoperative period and were included in the analysis. Of these, the median survival was 34 months (range 6 to 186 months) compared with 13 months (range 1 to 24 months) for those not undergoing curative surgery (P ≤ .001). Clinicopathologic factors favoring long-term survival were tumor size >3.5 cm (P ≤ .001) and T-stage ≤4 (P = .014).
Conclusions
Clinicopathologic factors important to survival in duodenal cancer are T4 tumor status and tumor size. Interestingly, larger tumors were less likely to be invasive, and patients with these tumors had improved survival. The biology of this cancer is poorly understood; therefore, aggressive resection for all duodenal adenocarcinomas is recommended for all patients medically fit to undergo resection.
ABSTRACT